Elicio Therapeutics, Inc.
ELTX
$10.60
-$0.43-3.90%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 5.78% | 19.96% | 25.66% | -160.59% | 38.88% |
| Total Depreciation and Amortization | 1.08% | -8.85% | 5.17% | -1.02% | 1.03% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 44.17% | -8.19% | -86.65% | 391.24% | -250.02% |
| Change in Net Operating Assets | 0.85% | -109.61% | 109.14% | 38.30% | 146.13% |
| Cash from Operations | 11.55% | -15.73% | -20.21% | 18.53% | 26.35% |
| Capital Expenditure | -- | -- | -- | 100.00% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -100.00% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | 100.00% | -1,500.00% |
| Total Debt Issued | -- | -- | -100.00% | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -80.00% | 4,449.78% | -98.04% | 3,563.29% | -97.13% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 100.00% | -- | -- |
| Cash from Financing | 15.53% | 4,449.78% | -99.26% | 9,632.28% | -97.13% |
| Foreign Exchange rate Adjustments | 138.71% | 14.81% | -25.00% | 187.80% | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1,173.33% | 102.81% | -136.29% | 370.45% | -694.06% |